Skip to content

Effect of Hormonal Contraception on Lower Urinary Tract Symptoms& Sexual Function

Effect of Hormonal Contraception on Lower Urinary Tract Symptoms& Sexual Function

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04336865
Enrollment
177
Registered
2020-04-07
Start date
2020-04-15
Completion date
2021-10-15
Last updated
2020-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contraception

Brief summary

Effect of hormonal contraception on lower urinary tract symptoms& sexual function

Detailed description

It is generally accepted that female sex hormones influence the morphology and physiology of vaginal tissues. Peripheral estrogen affects urogenital connective tissue composition and structure, vaginal blood flow, and thickness of vaginal epithelium. Estrogen and progestagen receptors are also abundantly present in the lower urinary tract, which has the same embryonic origin as the vagina. decline in circulating estrogen levels may result in atrophy of vaginal, urethral and bladder trigonal epithelium, as well as initiate metabolic changes in the subepithelial supportive tissues. This process forms the biological rationale for the common clinical practice of prescribing hormone treatment to menopausal women with lower urinary and genital tract symptoms. Contrary to widespread belief, the Womens Health Initiative (WHI) randomised trial showed that menopausal hormone therapy with conjugated estrogen alone, or in combination with progestagen, increased the risk of de novo or aggravated urinary incontinence after one year of treatment. In premenopausal women, oral contraception is the most common source of hormone intake but very few studies have endeavored to determine the effects of oral contraception on premenopausal urinary incontinence. The aim of this nationwide cohort study was to assess the influence of contraceptives on the risk for lower urinary tract dysfunction in young female.at is time-related with the beginning of hormonal contraception, health care providers should give information about other methods and try to switch them to a method less associated with sexual dysfunction. However, there are contradictory results between the different studies regarding the association between sexual dysfunction and hormonal contraceptives, so it could be firmly said that additional research is needed. Meanwhile, it could be said that hormonal contraception has been associated with different alterations in sexual functioning. To conclude, a multidisciplinary approach to the management of female sexual dysfunction is mandatory, and health care providers should give lifestyle counselling apart from proposing different treatment options. An adequate relationship with the patient, as well as the routine monitoring of possible sexual dysfunction, are essential in addressing these difficulties. Undoubtedly, the best contraceptive is one that fulfills the women's needs with acceptable side effects and agreed with the prescribed

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years

Inclusion criteria

1. Women taking hormonal contraception e.g cocs .pops.implanon&.injectable contraception 2. Women has good regular marital life

Exclusion criteria

1. female has organic urinary dysfunction 2. female has mental& psycological dysfunction 3. chronic disease DM.hypertension. chronic renal disease 4. prolapse 5. previous perineal &vaginal correlation surgery 6. women taking any treatment for urinary tract infection &sexual dysfunction

Design outcomes

Primary

MeasureTime frameDescription
Arabic female sexual function indexbaselinevalid questionnaire that can be used in the Egyptian population. The questionnaire is relatively easy to be understood by lay women and does not contain unacceptably sexually explicit questions, which may pose difficulties for self-rating. ArFSf I is valid and reliable,and it is as good as the original FSFI in assessing female sexual function &good psychometric tool for sexual dysfunction . Research in the area of female sexuality is not easy and relatively challenging in the Arab world
Bristol female lower urinary tract symptoms questionnairebaselineit was designed to asses lower urinary tract symptoms in women & quality of sexual life . it will be translated into arabic language

Countries

Egypt

Contacts

Primary Contactranda habeeb yacoup
randahabeb25@yahoo.com+201278014811

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026